■ Analysis · July 20, 2026
AbbVie's $10.9 Billion Apogee Acquisition: Dividend Implications
AbbVie's $10.9B acquisition of Apogee Therapeutics adds eczema drug zumilokibart; dividend likely unaffected due to debt financing and strong cash flow.
Acquisition Details and Dividend Concerns
On June 22, AbbVie (ABBV) announced the acquisition of Apogee Therapeutics for $10.9 billion in cash. The deal adds zumilokibart, an investigational eczema treatment, to AbbVie's immunology portfolio. Some investors question whether the large cash outlay could pressure the company's dividend program, a key attraction for income-focused shareholders. AbbVie ended 2025 with $17.8 billion in free cash flow, but the acquisition will be funded with debt, preserving cash reserves.
Dividend Track Record and Past Acquisitions
AbbVie is a Dividend King, with over 50 consecutive years of dividend increases when including its time under Abbott Laboratories. Management is committed to maintaining this streak. The company's largest acquisition, the $63 billion Allergan purchase in May 2020, did not harm dividends; since then, payouts have risen 46.6%. AbbVie's dividend history shows consistent growth.
Business Outlook and Growth Drivers
Zumilokibart could drive future revenue, earnings, and free cash flow, supporting the dividend program. AbbVie's current growth drivers include Skyrizi and Rinvoq, along with pipeline candidates in areas like weight loss. The Apogee acquisition is expected to strengthen AbbVie's immunology leadership and diversify its portfolio beyond Humira, similar to the Allergan deal which added Botox and Vraylar.
What it means for income investors
AbbVie's debt-funded acquisition and strong free cash flow suggest the dividend program remains secure. The company's track record of increasing dividends through major acquisitions provides context for income investors evaluating the stock.
Reporting based on: The Motley Fool. Figures verified against market data where available.